What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs

Drug Metabolism Reviews

Volumn 39, Issue 1, 2007, Pages 17-43

  Roffey, Sarah J ^a   Obach, R Scott ^a,b   Gedge, Jenny I ^a   Smith, Dennis A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

ADME; Covalent binding; Excretion; Mass balance; Nonspecific binding

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 7 (2 ACETYLTHIO 3 PHENYLPROPIONAMIDO) 1,2,3,4,6,7,8,12B OCTAHYDRO 6 OXOPYRIDO[2,1 A][2]BENZAZEPINE 4 CARBOXYLIC ACID; ABACAVIR; ALENDRONIC ACID; ALPIDEM; AMINOGLUTETHIMIDE; AMIODARONE; AMPRENAVIR; AZIMILIDE; BENAZEPRIL; BICALUTAMIDE; BIDISOMIDE; BISOPROLOL; BOSENTAN; BROMFENAC; BROMOCRIPTINE; BUNAZOSIN; CANDESARTAN; CAPECITABINE; CAPRAVIRINE; CAPTOPRIL; CARPROFEN; CARUMONAM; CARVEDILOL; CEFCANEL DALOXATE; EPTIFIBATIDE; ETRETIN; FLUOXETINE; GENTAMICIN; GI 1817771; HEXESTROL DERIVATIVE; PERHEXILINE; RITIPENEM ACOXIL; SANDOZ 58 112; SDZ FOX 988; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACCURACY; COVALENT BOND; DATA ANALYSIS; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; EXPERIMENTAL ANIMAL; HALF LIFE TIME; HUMAN; ISOTOPE LABELING; MASS BALANCE; METABOLITE; NONHUMAN; PATIENT COMPLIANCE; PROTEIN BINDING; RADIOACTIVITY; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SCIENTIFIC LITERATURE;

ANIMALS; FECES; HALF-LIFE; HUMANS; META-ANALYSIS; METABOLIC CLEARANCE RATE; PHARMACEUTICAL PREPARATIONS; RADIOISOTOPES; XENOBIOTICS;

EID: 33847081694     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.1080/03602530600952172     Document Type: Review

References (189)

1. Alton, K. B., Kosoglou, T., Baker, S., Affrime, M. B., Cayen, M. N., Patrick, J. E. (1998). Disposition of 14C-eptifibatide after intravenous administration to healthy men. Clin. Ther. 20(2):307-323.
2. Argenti, D., Jensen, B. K., Hensel, R., Bordeaux, K., Schleimer, R., Bickel, C., Heald, D. (2000). A mass balance study to evaluate the biotransformation and excretion of [14C]-triamcinolone acetonide following oral administration. J. Clin. Pharmacol. 40(7):770-780.
3. Assandri, A., Perazzi, A., Ferrari, P., Martinelli, E., Ripamonti, A., Tarzia, G., Tuan, G. (1985). Metabolic fate of zetidoline, a new neuroleptic agent, in man. Nauyn. Schmied. Arch. Pharmacol. 328(3):341-347.
4. Attar, M., Yu, D., Ni, J., Yu, Z., Ling, K. A. J., Tang-Liu, D. D. S. (2005). Disposition and biotransformation of the acetylenic retinoid tazarotene in humans. J. Pharm. Sci. 94(10):2246-2255.
5. Baker, S. D., Wirth, M., Statkevich, P., Reidenberg, P., Alton, K., Sartorius, S. E., Dugan, M., Cutler, D., Batra, V., Grochow, L. B., Donehower, R. C., Rowinsky, E. K. (1999). Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin. Cancer Res. 5(2): 309-317.
6. Balani, S. K., Woolf, E. J., Hoagland, V. L., Sturgill, M. G., Deutsch, P. J., Yeh, K. C., Lin, J. H. (1996). Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab. Dispos. 24(12):1389-1394.
7. Balani, S. K., Xu, X., Pratha, V., Koss, M. A., Amin, R. D., Dufresne, C., Miller, R. R., Arison, B. H., Doss, G. A., Chiba, M., Freeman, A., Holland, S. D., Schwartz, J. I., Lasseter, K. C., Gertz, B. J., Isenberg, J. I., Rogers, J. D., Lin, J. H., Baillie, T. A. (1997). Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metab. Dispos. 25(11):1282-1287.
8. Barbhaiya, R. H., Dandekar, K. A., Greene, D. S. (1996). Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans. Drug Metab. Dispos. 24(1):91-95.
9. Barbhaiya, R. H., Knupp, C. A., Forgue, S. T., Matzke, G. R., Halstenson, C. E., Opsahl, J. A., Pittman, K. A. (1991). Disposition of the cephalosporin cefepime in normal and renally impaired subjects. Drug Metab. Dispos. 19(1):68-73.
10. Beale, P., Judson, I., Hanwell, J., Berry, C., Aherne, W., Hickish, T., Martin, P., Walker, M. (1998). Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients. Cancer Chemother. Pharmacol. 42:71-76.
11. Beumer, J. H., Beijnen, J. H., Schellens, J. H. M. (2006). Mass balance studies, with a focus on anticancer drugs. Clin. Pharmacokinet. 45:33-58.
12. Beumer, J. H., Rademaker-Lakhai, J. M., Rosing, H., Lopez-Lazaro, L., Beijnen, J. H., Schellens, J. H. M. (2005). Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer. Inv. New Drugs 23(5):429-436.
13. Brunner, M., Kletter, K., Assandri, A., Corrado, M. E., Eichler, H. G., Mueller, M. (2002). Pharmacokinetic and mass balance study of unlabelled and 14C-labelled emedastine difumarate in healthy volunteers. Xenobiotica 32(9):761-770.
14. Bryce, T. A., Chamberlain, J., Hillbeck, D., Macdonald, C. M. (1989). Metabolism and pharmacokinetics of 14C-pentoxifylline in healthy volunteers. Arz.-Forsch. 39(4):512-517.
15. Brynne, N., Stahl, M. M. S., Hallen, B., Edlund, P. O., Palmer, L., Hoglund, P., Gabrielsson, J. (1997). Pharmacokinetics and pharmacodynamics of tolterodine in man. A new drug for the treatment of urinary bladder overactivity. Int. J. Clin. Pharmacol. Ther. 35(7):287-295.
16. Bu, H. Z., Pool, W. F., Wu, E. Y., Raber, S. R., Amantea, M. A., Shetty, B. V. (2004). Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab. Dispos. 32(7):689-698.
17. Caldwell, G. W., Wu, W. N., Masucci, J. A. (2001). Evaluation of the absorption, excretion and metabolism of [14C]etoperidone in man. Xenobiotica 31(11):823-839.
18. Caldwell, G. W., Wu, W. N., Masucci, J. A., McKown, L. A., Gauthier, D., Jones, W. J., Leo, G. C., Maryanoff, B. E. (2005). Metabolism and excretion of the antiepileptic/antimigraine drug, topiramate in animals and humans. Eur. J. Drug Metab. Pharmacokinet. 30(3):151-164.
19. Cocquyt, V., Kline, W. F., Gertz, B. J., Van Belle, S. J. P., Holland, S. D., DeSmet, M., Quan, H., Vyas, K. P., Zhang, K. E., De Greve, J., Porras, A. G. (1999). Pharmacokinetics of intravenous alendronate. J. Clin. Pharmacol. 39(4):385-393.
20. Colburn, W. A., Vane, F. M., Bugge, C. J. L., Carter, D. E., Bressler, R., Ehmann, C. W. (1985). Pharmacokinetics of 14C-isotretinoin in healthy volunteers and volunteers with biliary T-tube drainage. Drug Metab. Dispos. 13(3):327-332.
21. Cook, C. S., Ames, G. B., Smith, M. E., Kowalski, K. G., Karim, A. (1993). Absorption and disposition of a new antiarrhythmic agent bidisomide in man. Pharm. Res. 10(11):1675-1682.
22. Coombes, J. D. (1982). Metabolism of cefotaxime in animals and humans. Rev. Infect. Dis. 4(Suppl.):325-332.
23. Cox, P. J., Ryan, D. A., Hollis, F. J., Harris, A. M., Miller, A. K., Vousden, M., Cowley, H. (2000). Absorption, disposition and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer in humans. Drug Metab. Dispos. 28:772-780.
24. Crammer, J. L., Scott, B., Woods, H., Rolfe, B. (1968). Metabolism of 14C-imipramine. I. Excretion in rat and man. Psychopharmacologica 12:263-277.
25. Dain, J. G., Nicoletti, J., Ballard, F. (1997). Biotransformation of clozapine in humans. Drug Metab. Dispos. 25:603-609.
26. Dalgaard, L., Larsen, C. (1999). Metabolism and excretion of citalopram in man: identification of O-acyl- and N-glucuronides. Xenobiotica 29(10):1033-1041.
27. Dalrymple, P. D., Nicholls, P. J. (1984). Elimination of radioactivity in man following oral 14C-aminoglutethimide. IRCS Med. Sci. 12(1):48-49.
28. Davi, H., Carayon, A., Berthet, D., Cautreels, W., Dommisse, R., Faiez Zannad, M. D. (1986). Identification of urinary metabolites of penticainide in the rat, dog, baboon and man. Biomed. Env. Mass Spec. 13(10):559-568.
29. Davies, B., Morris, T. (1993). Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095.
30. Delbressine, L. P. C., Moonen, M. E. G., Kaspersen, F. M., Wagenaars, G. N., Jacobs, P. L., Timmer, C. J., Paanakker, J. E., van Hal, H. J. M., Voortman, G. (1998). Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin. Drug Invest. 15:45-55.
31. Denissen, J. F., Grabowski, B. A., Johnson, M. K., Buko, A. M., Kempf, D. J., Thomas, S. B., Surber, B. W. (1997). Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538)in rats, dogs, and humans. Drug Metab. Dispos. 25(4):489-501.
32. de Vries, P. J., Oosterhuis, B., van Boxtel, C. J. (1994). Single-dose pharmacokinetics of chloroquine and its main metabolite in healthy volunteers. Drug Invest. 8:143-149.
33. Durand, A., Thenot, J. P., Bianchetti, G., Morselli, P. L.(1992). Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. Drug Metab. Rev. 24(2):239-266.
34. Durham, S. L., Hoke, J. F., Chen, T. M. (1993). Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. Drug Metab. Dispos. 21(3):480-484.
35. Eckert, H. G., Badian, M. J., Gantz, D., Kellner, H. M., Volz, M. (1984). Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3- phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man. Arz.-Forsch. 34(10B):1435-1447.
36. Edwall, B., Arvidsson, A., Lake-Bakaar, D., Lanbeck-Vallen, K., Yisak, W. (1993). Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects. Drug Metab. Dispos. 21(1):171-177.
37. Efthymiopoulos, C., Strolin Benedetti, M., Sassella, D., Boobis, A., Davies, D. (1992). Pharmacokinetics of [14C]FCE 22891, a penem antibiotic, following oral administration to healthy volunteers. Antimic. Agents Chemother. 36(9):1958-1963.
38. Egger, H., Kochak, G., Robertson, P., Iannucci, R., Rufino, F. A., Stancato, F. (1989). Physiological disposition of CGS 16617 in rat, dog, and man. Drug Metab. Dispos. 17(6):669-672.
39. Ericsson, H., Hamren, B., Bergstrand, S., Elebring, M., Fryklund, L., Heijer, M., Oehman, K. P. (2004). Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor a/g agonist, after a single oral and intravenous dose in humans. Drug Metab. Dispos. 32(9):923-929.
40. Eriksson, B., Brorsson, A. K., Ottersgard, H. G., Sjodin, T., Gunnarsson, P. O. (1998). Pharmacokinetics of 14C-delmopinol in the healthy male volunteer. Xenobiotica 28(11):1075-1081.
41. Ferrero, J. L., Bopp, B. A., Marsh, K. C., Quigley, S. C., Johnson, M. J., Anderson, D. J., Lamm, J. E., Tolman, K. G., Sanders, S. W., Cavanaugh, J. H. (1990). Metabolism and disposition of clarithromycin in man. Drug Metab. Dispos. 18(4):441-446.
42. Filer, C. W., Allen, G. D., Brown, T. A., Fowles, S. E., Hollis, F. J., Mort, E. E., Prince, W. T., Ramji, J. V. (1994). Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects. Xenobiotica 24(4):357-368.
43. Fischer, V., Baldeck, J. P., Tse, F. L. S. (1992). Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans. Drug Metab. Dispos. 20(4):603-607.
44. Franklin, R. A., Norris, R., Shepherd, N. W., Rhenius, S. T. (1984). Preliminary studies on the fate of 14C-fentiazac in man. Xenobiotica 14(12):955-960.
45. Franklin, R. A., Robson, P., Stevenson, D. (1983). Studies on the metabolism of the new antihypertensive agent, indoramin, in man. Eur. J. Clin. Pharmacol. 24(5):629-634.
46. Fromson, J. M., Pearson, S., Bramah, S. (1973). The metabolism of tamoxifen (ICI, 46, 474) part II: In female patients. Xenobiotica 3:711-714.
47. Garner, R. C., Goris, I., Laenen, A. A. E., Vanhoutte, E., Meuldermans, W., Gregory, S., Garner, J. V., Leong, D., Whattam, M., Calam, A., Snel, C. A. W. (2002). Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl) -1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. Drug Metab. Dispos. 30(7):823-830.
48. Grindel, J. M., O'Neill, P. J., Yorgey, K. A., Schwartz, M. H., McKown, L. A., Migdalof, B. H., Wu, W. N. (1980). The metabolism of zomepirac sodium. I. Disposition in laboratory animals and man. Drug Metab. Dispos. 8(5):343-348.
49. Grislain, L., Gele, P., Bertrand, M., Luijten, W., Bromet, N., Salvadori, C., Kamoun, A. (1990). The metabolic pathways of tianeptine, a new antidepressant in healthy volunteers. Drug Metab. Dispos. 18:804-808.
50. Gschwind, H. P., Pfaar, U., Waldmeier, F., Zollinger, M., Sayer, C., Zbinden, P., Hayes, M., Pokorny, R., Seiberling, M., Ben-Am, M., Peng, B., Gross, G. (2005). Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab. Dispos. 33(10):1503-1512.
51. Halpin, R. A., Porras, A. G., Geer, L. A., Davis, M. R., Cui, D., Doss, G. A., Woolf, E., Musson, D., Matthews, C., Mazenko, R., Schwartz, J. I., Lasseter, K. C., Vyas, K. P., Baillie,T. A. (2002). The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects. Drug Metab. Dispos. 30(6):684-693.
52. Harrison, M. P., Haworth, S. J., Moss, S. R., Wilkinson, D. M., Featherstone, A. (1993). The disposition and metabolic fate of 14C-meropenem in man. Xenobiotica 23(11):1311-1323.
53. Heller, D. P., Burke, S. K., Davidson, D. M., Donovan, J. M. (2002). Absorption of colesevelam hydrochloride in healthy volunteers. Ann. Pharmacother. 36(3):398-403.
54. Howell, S. R., Husbands, G. E. M., Scatina, J. A., Sisenwine, S. F. (1993). Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 23(4):349-359.
55. Huempel, M., Krause, W., Hoyer, G. A., Wendt, H., Pommerenke, G. (1984). The pharmacokinetics and biotransformation of 14C-lisuride hydrogen maleate in rhesus monkey and in man. Eur. J. Drug Metab. Pharmacokinet. 9(4):347-357.
56. Iyer, R. A., Mitroka, J., Malhotra, B., Bonacorsi, S., Waller, S. C., Rinehart, J. K., Roongta, V. A., Kripalani, K. (2001). Metabolism of [14C] omapatrilat, a sulphydryl-containing vasopeptidase inhibitor in humans. Drug Metab. Dispos. 29:60-69.
57. Johnson, K., Shah, A., Jaw-Tsai, S., Baxter, J., Prakash, C. (2003). Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers. Drug Metab. Dispos. 31(1):76-87.
58. Jorga, K., Fotteler, B., Heizmann, P., Gasser, R. (1999). Metabolism and excretion of tolcapone, a novel inhibitor of catechol-o-methyltransferase. Br. J. Clin. Pharmacol. 48:513-520.
59. Joshi, A. S. (2001). Elimination pathways of [14C]losoxantrone in four cancer patients. Drug Metab. Dispos. 29(2):96-99.
60. Judson, I. R., Beale, P. J., Trigo, J. M., Aherne, W., Crompton, T., Jones, D., Bush, E., Reigner, B. (1999). A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest. New Drugs 17(1):49-56.
61. Kadar, D., Fecycz, T. D., Kalow, W. (1983). The fate of orally administered [4-14C]phenytoin in two healthy male volunteers. Can. J. Physiol. Pharmacol. 61(4):403-407.
62. Kassahun, K., Mattiuz, E., Nyhart, E., Obermeyer, B., Gillespie, T., Murphy, A., Goodwin, R. M., Tupper, D., Callaghan, J. T., Lemberger, L. (1997). Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab. Dispos. 25(1):81-93.
63. Klunk, L. J., Ringel, S., Neiss, E. S. (1983). The disposition of 14C-indapamide in man. J.Clin. Pharmacol. 23(8-9):377-384.
64. Klunk, L. J., Riska, P. S., Maynard, D. E. (1982). The disposition and metabolism of 14Ctiaramide. hydrochloride in man. Drug Metab. Dispos. 10(3):241-245.
65. Kollias, N., Baqer, A. (1986). On the assessment of melanin in human skin in vivo. Photochem. Photobiol. 43(1):49-54.
66. Krieter, P., Flannery, B., Musick, T., Gohdes, M., Martinho, M., Courtney, R. (2004). Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimic. Agents Chemother. 48(9):3543-3551.
67. Kripalani, K. J., McKinstry, D. N., Singhvi, S. M., Wilard, D. A., Vukovich, R. A., Migdalof, B. H. (1980). Disposition of captopril in normal subjects. Clin. Pharmacol. Ther. 27:636-641.
68. Lantz, R. J., Gillespie, T. A., Rash, T. J., Kuo, F., Skinner, M., Kuan, H. Y., Knadler, M. P. (2003). Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab. Dispos. 31(9):1142-1150.
69. Larsson, B., Tjalve, H. (1979). Studies on the mechanism of drug-binding to melanin. Biochem. Pharmacol. 28:1181-1187.
70. Latini, R., Tognoni, G., Kates, R. E. (1984). Clinical pharmacokinetics and amiodarone. Clin. Pharmacokinet. 9:136-156.
71. Lau, D. T. W., Kalafsky, G., Tse, F. L. S. (1995). The effect of food on the absorption of 14C-SDZ FOX 988, an antidiabetic agent, in healthy human volunteers. Biopharm. Drug Dispos. 16(3):191-200.
72. Leblanc, B., Jezequel, S., Davies, T., Hanton, G., Taradach, C. (1998). Binding of drugs to eye melanin is not predictive of ocular toxicity. Reg. Toxicol. Pharmacol. 28(2):124-132.
73. Lemberger, L., Bergstrom, R. F., Wolen, R. L., Farid, N. A., Enas, G. G., Aronoff, G. R. (1985). Fluoxetine: clinical pharmacology and physiologic disposition. J. Clin. Psych. 46(3, Sec. 2):14-19.
74. Leopold, G., Pabst, J., Ungethuem, W., Buehring, K. U. (1986). Basic pharmacokinetics of bisoprolol, a new highly beta1-selective adrenoceptor antagonist. J. Clin.Pharmacol. 26(8):616-621.
75. Lin, C. C., Chung, M., Gural, R., Schuessler, D., Kim, H. K., Radwanski, E., Marco, A., DiGiore, C., Symchowicz, S. (1984). Pharmacokinetics and metabolism of rosaramicin in humans. Antimic. Agents Chemother. 26(4):522-526.
76. Lins, R., Broekhuysen, J., Necciari, J., Deroubaix, X. (1999). Pharmacokinetic profile of 14C-labeled clopidogrel. Sem. Thrombosis Hemostasis 25(Suppl. 2):29-33.
77. Mahon, G. J., Anderson, H. R., Gardiner, T. A., McFarlane, S., Archer, D. B., Stitt, A. W. (2004). Chloroquine causes lysosomal dysfunction in neural retina and RPE: Implications for retinopathy. Curr. Eye Res. 28:277-284.
78. Mangold, J. B., Gu, H., Rodriguez, L. C., Bonner, J., Dickson, J., Rordorf, C. (2004). Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab. Dispos. 32(5):566-571.
79. Mangold, J. B., Schran, H. F., Tse, F. L. S. (1994). Pharmacokinetics and metabolism of cyclosporin G in humans. Drug Metab. Dispos. 22(6):873-879.
80. Mannens, G., Huang, M. L., Meuldermans, W., Hendrickx, J., Woestenborghs, R., Heykants, J. (1993). Absorption, metabolism, and excretion of risperidone in humans. Drug Metab. Dispos. 21(6):1134-1141.
81. Martin, P. D., Warwick, M. J., Dane, A. L., Hill, S. J., Giles, P. B., Phillips, P. J., Lenz, E. (2003). Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin. Ther. 25(11):2822-2835.
82. Massarella, J. W., Loh, A. C., Williams, T. H., Szuna, A. J., Sandor, D., Bressler, R., Leinweber, F. J. (1986). The disposition and metabolic fate of 14C-cibenzoline in man. Drug Metab. Dispos. 14(1):59-64.
83. Maurer, G., Schreier, E., Delaborde, S., Nufer, R., Shukla, A. P. (1983). Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism. Eur. J. Drug Metab. Pharmacokinet. 8(1):51-62.
84. McDowell, J. A., Chittick, G. E., Ravitch, J. R., Polk, R. E., Kerkering, T. M., Stein, D. S. (1999). Pharmacokinetics of [14C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: A mass balance study. Antimic. Agents Chemother. 43(12):2855-2861.
85. McKillop, D., Boyle, G. W., Cockshott, I. D., Jones, D. C., Phillips, P. J., Yates, R. A. (1993). Metabolism and enantioselective pharmacokinetics of Casodex in man. Xenobiotica 23(11):1241-1253.
86. McQuinn, R. L., Quarfoth, G. J., Johnson, J. D., Banitt, E. H., Pathre, S. V., Chang, S. F., Ober, R. E., Conard, G. J. (1984). Biotransformation and elimination of 14C-flecainide acetate in humans. Drug Metab. Dispos. 12(4):414-420.
87. Meuldermans, W., Hendrickx, J., Woestenborghs, R., Van Peer, A., Lauwers, W., De Cree, J., Heykants, J. (1988). Absorption, metabolism and excretion of ketanserin in man after oral administration. Arz.-Forsch. 38(6):789-794.
88. Meuldermans, W., Hurkmans, R., Swysen, E., Hendrickx, J., Michiels, M., Lauwers, W., Heykants, J. (1981). On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur. J. Drug Metab. Pharmacokinet. 6(1):49-60.
89. Midgley, I., Chasseaud, L. F., Taylor, T., Darragh, A. (1982). The absorption and excretion of 14Clofexidine hydrochloride in man. Arz.-Forsch. 32(8A):972-975.
90. Midgley, I., Fowkes, A. G., Darragh, A., Lambe, R., Chasseaud, L. F., Taylor, T. (1983). The metabolic fate of the anti-androgenic agent, oxendolone, in man. Steroids 41(4):521-536.
91. Mitchell, S. C., Idle J. R., Smith, R. L. (1982). The metabolism of [14C]cimetidine in man. Xenobiotica 12(5):283-292.
92. Miyamoto, G., Sasabe, H., Tominaga, N., Uegaki, N., Tominaga, M., Shimizu, T. (1988). Metabolism of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl0-1-piperazinyl]-2(1H)-quinolinone (OPC-8212) in the rat, mouse, dog, monkey, and human. Xenobiotica 18(10):1143-1155.
93. Molimard, M., Diquet, B., Strolin Benedetti, M. (2004). Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fund. Clin. Pharmacol. 18(4):399-411.
94. Moller, A., Iwasaki, K., Kawamura, A., Teramura, Y., Shiraga, T., Hata, T., Schafer, A., Undre, N. A. (1999). The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab. Dispos. 27(6):633-636.
95. Morishita, N., Tomono, Y., Hasegawa, J., Yuzuriha, T., Giese, U. (1993). Absorption, elimination and metabolic fate of bunazosin in 3 healthy male volunteers. Drug Invest. 5(6):296-301.
96. Mroszczak, E. J., Lee, F. W. (1980). Tiopinac absorption, distribution, excretion, and pharmacokinetics in man and animals. Drug Metab. Dispos. 8(6):415-421.
97. Murayama, N., McMahon, H., Young, C. G., McCracken, N. W., Okamura, Y., Hakusui, H., Tanaka, M. (2000). Pharmacokinetics of the anticoagulant 14C-DX-9065a in the healthy male volunteer after a single intravenous dose. Xenobiotica 30(5):515-521.
98. Nagai, J., Tanaka, H., Nakanishi, N., Murakami, T., Takano, M. (2001). Role of megalin in renal handling of aminoglycosides. Am. J. Physiol. 281:F337-F344.
99. Nave, R., Bethke, T. D., Van Marle, S. P., Zech, K. (2004). Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin. Pharmacokinet. 43(7):479-486.
100. Neugebauer, G., Akpan, W., Von Moellendorff, E., Neubert, P., Reiff, K. (1987). Pharmacokinetics and disposition of carvedilol in humans. J. Cardiovasc. Pharmacol.10(Suppl. 11):S85-S88.
101. Norrby, S. R., Rogers, J. D., Ferber, F., Jones, K. H., Zacchei, A. G., Weidner, L. L., Demetriades, J. L., Gravallese, D. A., Hsieh, J. Y. K. (1984). Disposition of radiolabeled imipenem and cilastatin in normal human volunteers. Antimic. Agents Chemother. 26(5):707-714.
102. Ono, C., Yamado, M., Tanaka, M. (2003). Absorption, distribution and excretion of 14C-chloroquine after single oral administration in albino and pigmented rats: Binding characteristics of chloroquine related radioactivity to melanin in vivo. J. Pharm. Pharmacol. 55:1647-1654.
103. Osman, M., Chandrasekaran, A., Chan, K., Scatina, J., Ermer, J., Cevallos, W., Sisenwine, S. F. (1998). Metabolic disposition of 14C-bromfenac in healthy male volunteers. J. Clin. Pharmacol. 38(8):744-752.
104. Patrick, J. E., Kosoglou, T., Stauber, K. L., Alton, K. B., Maxwell, S. E., Zhu, Y., Statkevich, P., Iannucci, R., Chowdhury, S., Affrime, M., Cayen, M. N. (2002). Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab. Dispos. 30(4):430-437.
105. Paulson, S. K., Hribar, J. D., Liu, N. W. K., Hajdu, E., Bible, R. H., Piergies, A., Karim, A. (2000). Metabolism and excretion of [14C]celecoxib in healthy male volunteers. Drug Metab. Dispos. 28(3):308-314.
106. Peck, R. W., Wootton, R., Lee, D. R., Jackson, S. H. D., Posner, J. (1995). The bioavailability and disposition of 1-(b-D-arabinofuranosyl)-5-(1- propynyl)uracil (882C87), a potent, new antivaricella zoster virus agent. Br. J. Clin. Pharmacol. 39(2):143-149.
107. Peeters, P. A. M., Van Lier, J. J., Van de Merbel, N., Oosterhuis, B., Wieling, J., Jonkman, J. H. G., Klessing, K., Biber, A. (1998). Pharmacokinetics of [14C]-labeled losigamone and enantiomers after oral administration to healthy subjects. Eur. J. Drug Metab. Pharmacokinet. 23(1):45-53.
108. Pentikainen, P. J., Neuvonen, P. J., Penttila, A. (1983). Pharmacokinetics and pharmacodynamics of glipizide in health volunteers. Int. J. Clin. Pharmacol. Ther. Toxicol. 21(2):98-107.
109. Pentikainen, P. J., Penttila, A., Neuvonen, P. J., Khalifah, R. G., Hignite, C. E. (1982). Human metabolism of tolfenamic acid. I. Isolation, preliminary characterization and pharmacokinetics of tolfenamic acid and its metabolites. Eur. J.Drug Metab. Pharmacokinet. 7(4):259-267.
110. Pieniaszek, H. J., Davidson, A. F., Chaney, J. E., Shum, L., Robinson, C. A., Mayersohn, M. (1999). Human moricizine metabolism. II. Quantification and pharmacokinetics of plasma and urinary metabolites. Xenobiotica 29(9):945-955.
111. Plozza-Nottebrock, H., Stoeckel, K., Vergin, H. (1982). Pharmacokinetics of metioprim (Ro 12-6995) in humans. Curr. Chemother. Immunother. (Proc. 12th Int. Congr. Chemother.) 2:946-947.
112. Pool, W. F., Reily, M. D., Bjorge, S. M., Woolf, T. F. (1997). Metabolic disposition of the cognition activator tacrine in rats, dogs, and humans. Species comparisons. Drug Metab. Dispos. 25:590-597.
113. Ray, J. E., Wade, D. N. (1982). The pharmacokinetics and metabolism of 14C-carprofen in man. Biopharm. Drug Dispos. 3(1):29-38.
114. Reasor, M. J., Kacew, S. (2001). Drug induced phospholipidosis: Are there functional consequences? Exp. Biol. Med. 226:825-830.
115. Regaardh, C. G., Andersson, T., Lagerstroem, P. O., Lundborg, P., Skaanberg, I. (1990). The pharmacokinetics of omeprazole in humans - a study of single intravenous and oral doses. Ther. Drug Monit. 12(2):163-172.
116. Reith, K., Keung, A., Toren, P. C., Cheng, L., Eller, M. G., Weir, S. J. (1988). Disposition and metabolism of 14C-rifapentine in healthy volunteers. Drug Metab. Dispos. 26(8):732-738.
117. Reith, M. K., Sproles, G. D., Cheng, L. K. (1995). Human metabolism of dolasetron mesylate, a 5-HT3 receptor antagonist. Drug Metab. Dispos. 23(8):806-812.
118. Renwick, A. G., Pettet, J. L., Gruchy, B., Corina, D. L. (1982). The fate of [14C]trithiozine in man. Xenobiotica 12(5):329-343.
119. Riley, P., Figary, P. C., Entwisle, J. R., Roe, A. L., Thompson, G. A., Ohashi, R., Ohashi, N., Moorehead, T. J. (2005). The metabolic profile of azimilide in man: In vivo and in vitro evaluations. J. Pharm. Sci. 94(9):2084-2095.
120. Riska, P., Lamson, M., Macgregor, T., Sabo, J., Hattox, S., Pav, J., Keirns, J. (1999). Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab. Dispos. 27(8):895-901.
121. Roberts, A., Renwick, A. G., Sims, J., Snodin, D. J. (2000). Sucralose metabolism and pharmacokinetics in man. Food Chem. Toxicol. 38(Suppl. 2):S31-S41.
122. Rodrigues, A. D., Halpin, R. A., Geer, L. A., Cui, D., Woolf, E. J., Matthews, C. Z., Gottesdiener, K. M., Larson, P. J., Lasseter, K. C., Agrawal, N. G. B. (2003). Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab. Dispos. 31(2):224-232.
123. Roth, W., Bauer, E., Heinzel, G., Cornelissen, P. J. G., Van Tol, R. G. L., Jonkman, J. H. G., Zuiderwijk, P. B. M. (1993). Zatebradine: Pharmacokinetics of a novel heart-rate-lowering agent after intravenous infusion and oral administration to healthy subjects. J. Pharm. Sci. 82(1):99-106.
124. Roth, W., Koss, F. W., Hallinan, D., Lambe, R., Darragh, A. (1990). Pharmacokinetics of falipamil after intravenous administration to humans. J. Pharm. Sci. 79(5):415-419.
125. Rubio, F., Jensen, B. K., Henderson, L., Garland, W. A., Szuna, A., Town, C. (1994). Disposition of [14C]acitretin in humans following oral administration. Drug Metab. Dispos. 22(2):211-215.
126. Rush, W. R., Alexander, O., Hall, D. J., Cairncross, L., Dow, R. J., Graham, D. J. G. (1986). The metabolism of nicardipine hydrochloride in healthy male volunteers. Xenobiotica 16(4):341-349.
127. Sadler, B. M., Chittick, G. E., Polk, R. E., Slain, D., Kerkering, T. M., Studenberg, S. D., Lou, Y., Moore, K. H. P., Woolley, J. L., Stein, D. S. (2001). Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects. J. Clin. Pharmacol. 41(4):386-396.
128. Seaber, E., On, N., Dixon, R. M., Gibbens, M., Leavens, W. J., Liptrot, J., Chittick, G., Posner, J., Rolan, P. E., Peck, R. W. (1997). The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (3 I I C90). Br. J. Clin. Pharmacol. 43(6):579-587.
129. Shah, B., Emmons, G., Rohatagi, S., Martin, N. E., Jensen, B. K. (2003). Mass balance study of [14C]M100240, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy male subjects. Am. J. Ther.10(5):356-362.
130. Shumaker, R. C., Fantel, C., Kelton, E., Wong, K., Weliky, I. (1990). Evaluation of the elimination of (14C) felbamate in healthy men. Epiliepsia 31(5):642.
131. Simons, P. J., Cockshott, I. D., Douglas, E. J., Gordon, E. A., Hopkins, K., Rowland, M. (1988). Disposition in male volunteers of a subanesthetic intravenous dose of an oil in water emulsion of 14C-propofol. Xenobiotica 18(4):429-440.
132. Singhvi, S. M., Duchin, K. .L, Morrison, R. A., Willard, D. A., Everett, D. W., Frantz, M. (1988). Disposition of fosinopril sodium in healthy subjects. Br. J. Clin. Pharmacol. 25(1):9-15.
133. Singhvi, S. M., Foley, J. E., Willard, D. A., Morrison, R. A. (1990a). Disposition of zofenopril calcium in healthy subjects. J. Pharm. Sci. 79(11):970-973.
134. Singhvi, S. M., Pan, H. Y., Morrison, R. A., Willard, D. A. (1990b). Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 29(2):239-243.
135. Sisenwine, S. F., Liu, A. L., Tio, C., Kimmel, H., Freeland, G. (1986). The metabolic disposition of 14C-ciramadol in humans. Xenobiotica 16(4):335-340.
136. Slatter, J. G., Schaaf, L. J., Sams, J. P., Feenstra, K. L., Johnson, M. G., Bombardt, P. A., Cathcart, K. S., Verburg, M. T., Pearson, L. K., Compton, L. D., Miller, L. L., Baker, D. S., Pesheck, C. V., Lord, R. S. (2000). Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following i.v. infusion of [14C]CPT-11 in cancer patients. Drug Metab. Dispos. 28(4):423-433.
137. Slatter, J. G., Stalker, D. J., Feenstra, K. L., Welshman, I. R., Bruss, J. B., Sams, J. P., Johnson, M. G., Sanders, P. E., Hauer, M. J., Fagerness, P. E., Stryd, R. P., Peng, G. W., Shobe, E. M. (2001). Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14C]linezolid to healthy human subjects. Drug Metab. Dispos. 29(8):1136-1145.
138. Slattery, J. T., Wilson, J. M., Kalhorn, T. F., Nelson, S. D. (1987). Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans. Clin. Pharmacol.Ther. 41:413-418.
139. Smith, D. A., Obach, R. S. (2005). Seeing through the MIST: Abundance vs percentage. commentary on metabolites in safety testing. Drug Metab. Dispos. 33:1409-1417.
140. Soul-Lawton, J., Seaber, E., On, N., Wootton, R., Rolan, P., Posner, J. (1995). Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimic. Agents Chemother. 39(12):2759-2764.
141. Stoltz, R., Parisi, S., Shah, A., Macciocchi, A. (2004). Pharmacokinetics, metabolism and excretion of intravenous [14C]-palonosetron in healthy human volunteers. Biopharm. Drug Dispos. 25(8):329-337.
142. Strolin Benedetti, M., Plisnier, M., Kaise, J., Maier, L., Baltes, E., Arendt, C., McCracken, N. (2001). Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Eur. J. Clin. Pharmacol. 57(8):571-582.
143. Sunzel, M. (2004). In: C.G. Sahajwalla, ed. New Drug Development, Regulatory Paradigms for Clinical Pharamcology and Biopharmaceutics. New York: Marcel Decker, pp. 187-212.
144. Takadoro, T., Kobayashi, N., Zmudzka, B. Z., Ito, S., Wakamatsu, K., Yamaguchi, Y., Korossy, K. S., Miller, S. A., Beer, J. Z., Hearing, V. J. (2003). UV-Induced DNA damage and melanin content in human skin differing in racial ethnic origin. FASEB J. 17:1177-1179.
145. Timmer, C. J., Ad Sitsen, J. M., Delbressine, L. P. (2000). Clinical pharmacokinetics of mirtazapine. Clin. Pharmacokinet. 38:461-474.
146. Tiseo, P. J., Perdomo, C. A., Friedhoff, L. T. (1998). Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. Br. J. Clin. Pharmacol. 46(Suppl. 1):19-24.
147. Toler, S. M. (2004). Oxidative stress plays an important role in the pathogenesis of drug-induced retinopathy. Exp. Biol. Med. 229:607-615.
148. Toler, S. M. (2005). Fluphenazine augments retinal oxidative stress. J. Ocular Pharmacol. Therap. 21:259-265.
149. Tomori, E., Horvath, G., Patfalusi, M., Meszaros, S., Vereczkey, L. (1992). Pharmacokinetic and metabolism studies on girisopam by chromatographic and spectrometric methods in humans. J. Chrom. 578(1):91-101.
150. Toon, S., Heimark, L. D., Trager, W. F., O'Reilly, R. A.(1985). Metabolic fate of phenprocoumon in humans. J. Pharm Sci. 74(10):1037-1040.
151. Tse, F. L. S. (1995). Pharmacokinetics in drug discovery and development: nonclinical studies. In: P. G. Welling and F. L. S. Tse, eds. Pharmacokinetics. Regulatory, Industrial, Academic Perspectives. New York: Marcel Dekker, Inc. pp. 281-334.
152. Tse, F. L. S., Jaffe, J. M. (1987a). Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man. Eur. J. Clin. Pharmacol. 32(4):361-365.
153. Tse, F. L. S., Jaffe, J. M., Bhuta, S. (1987b). Pharmacokinetics of orally administered tizanidine in healthy volunteers. Fund. Clin. Pharmacol. 1(6):479-488.
154. Tse, F. L. S., Jaffe, J. M., Dain, J. G. (1984). Pharmacokinetics of compound 58-112, a potential skeletal muscle relaxant, in man. J. Clin. Pharmacol. 24(1):47-57.
155. Turcan, R. G., Hillbeck, D., Hartley, T. E., Gilbert, P. J., Coe, R. A. J., Troke, J. A., Vose, C. W. (1992). Disposition of [14C]velnacrine maleate in rats, dogs, and humans. Drug Metab. Dispos. 21(6):1037-1047.
156. van den Bongard, H. J. G. D., Plium, D., Rosing, H., Nan-Offeringa, L., Schot, M., Ravic, M., Schellens, J. H. M., Beijnen, J. H. (2002). An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients. Anti-Cancer Drugs 13(8):807-814.
157. van Heiningen, P. N. M., Hatorp, V., Kramer Nielsen, K., Hansen, K. T., van Lier, J. J., De Merbel, N. C., Oosterhuis, B., Jonkman, J. H. G. (1999). Absorption, metabolism and excretion of a single oral dose of 14C-repaglinide during repaglinide multiple dosing. Eur. J. Clin. Pharmacol. 55(7):521-525.
158. van Lier, J. J., van Heiningen, P. N. M., Sunzel, M. (1997). Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers. J. Hum. Hyperten. 11(Suppl. 2):S27-S28.
159. Vargay, Z., Deutsch, T., Szatmari, I., Szuts, T., Varkonyi, T., Kerpel-Fronius, S., Eckhardt, S. (1984). The fate of Drotaverine-Acephyllinate in rat and man. II. Human pharmacokinetics of Drotaverine-14C-Acephyllinate. Eur. J. Drug Metab. Pharmacokinet. 9(1):17-29.
160. Vincent, J., Teng, R., Dalvie, D. K., Friedman, H. L. (1998). Pharmacokinetics and metabolism of single doses of trovafloxacin. Am. J. Surg. 176(Suppl 6A):85-135.
161. Vinge, E., Midskov, C., Arnold, E. (1986). Pharmacokinetics of 14C-fenflumizole after intravenous administration to man. Acta Pharmacol. Toxicol. 58(5):355-362.
162. Vitiello, B., Buniva, G., Bernareggi, A., Assandri, A., Perazzi, A., Fuccella, L. M., Palumbo, R. (1984). Pharmacokinetics and metabolism of premazepam, a new potential anxiolytic, in humans. Int. J. Clin. Pharmacol. Ther. Toxicol. 22(5):273-277.
163. Vollmer, K. O., Poisson, A. (1985). Metabolism of thymoxamine. II. Studies with 14C-thymoxamine in man. Eur. J. Drug Metab. Pharmacokinet. 10(1):71-76.
164. Vos, R. M. E., Krebbers, S. F. M., Verhoeven, C. H. J., Delbressine, L. P. C. (2002). The in vivo human metabolism of tibolone. Drug Metab. Dispos. 30(2):106-112.
165. Vree, T. B., Waitzinger, J., Hammermaier, A., Radhofer-Welte, S. (1999). Absolute bioavailability, pharmacokinetics, renal, and biliary clearance of distigmine after a single oral dose in comparison to i.v. administration of 14C-distigmine-bromide in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 37(8):393-403.
166. Vyas, K. P., Halpin, R. A., Geer, L. A., Ellis, J. D., Liu, L., Cheng, H., Chavez-Eng, C., Matuszewski, B. K., Varga, S. L., Guiblin, A. R., Rogers, J. D. (2000). Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. Drug Metab. Dispos. 28(1):89-95.
167. 14C]gemopatrilat after oral administration to rats, dogs, and humans. Drug Metab. Dispos. 34:961-970.
168. Waldmeier, F., Kaiser, G., Ackermann, R., Faigle, J. W., Wagner, J., Barner, A., Lasseter, K. C. (1991). The disposition of [14C]-labelled benazepril hydrochloride in normal adult volunteers after single and repeated oral dose. Xenobiotica 21(2):251-261.
169. Walker, O., Salako, L. A., Alvan, G., Ericsson, O., Sjoqvist, F. S. (1987). The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. Br. J. Clin. Pharmacol. 23:295-301.
170. Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., Walle, U. K. (2004). High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32(12):1377-1382.
171. Washio, T., Kohsaka, K., Arisawa, H., Masunaga, H., Nagatsuka, S. I., Satoh, Y. (2003). Pharmacokinetics and metabolism of radiolabeled SNI-2011, a novel muscarinic receptor agonist, in healthy volunteers: Comprehensive understanding of absorption, metabolism and excretion using radiolabeled SNI-2011. Arz.-Forsch. 53(2):80-86.
172. Webber, C., Roth, A., Persiani, S., Peard, A. J., Makovec, F., Kapil, R. P., John, B. A., Holding, J. D., D'Amato, M., Cybulski, Z. R., Chasseaud, L. F., Rovati, L. C. (2003). Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects. Xenobiotica 33(6):625-641.
173. Weber, C., Gasser, R., Hopfgartner, G. (1999). Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab. Dispos. 27(7):810-815.
174. Weidekamm, E., Stoeckel, K., Egger, H. J., Ziegler, W. H. (1984). Single-dose pharmacokinetics of Ro 17-2301 (AMA-1080), a monocyclic b-lactam, in humans. Antimic. Agents Chemother. 26(6):898-902.
175. Weil, A., Caldwell, J., Strolin-Benedetti, M. (1990). The metabolism and disposition of 14Cfenofibrate in human volunteers. Drug Metab. Dispos. 18(1):115-120.
176. Widman, M., Nilsson, L. B., Bryske, B., Lundstrom, J. (1993). Disposition of remoxipride in different species. Arz.-Forsch. 43(3):287-297.
177. Wilson, I. D., Fromson, J. M., Illing, H. P. A., Schraven, E. (1987). The metabolism of [14C]N-ethoxycarbonyl-3-morpholinosydnone imine (molsidomine) in man. Xenobiotica 17(1):93-104.
178. Winslade, N. E., Adelman, M. H., Evans, E. J., Schentag, J. J.( 1987). Single-dose accumulation pharmacokinetics of tobramycin and netimicin in normal volunteers. Antimicrob. Agents Chemother. 31:605-609.
179. Winternitz, P. F., Dulcire, B., Crawley, Y. (1987). Pharmacokinetics and metabolism of diosmin. Proc. Eur. Congr. Biopharm. Pharmacokinet. 2:658-664.
180. Wong, B. K., Xu, X., Yu, S., Lin, J. H., Singh, R., Sahly, Y., Mistry, G., Holland, S., Waldman, S., Musson, D., Majumdar, A. (2004). Comparative disposition of [14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man. Xenobiotica 34(4):379-389.
181. Wong, F. A., Lloyd, J. R., Graden, D. W. (1990). The metabolism of etintidine in rat, dog, and human. Drug Metab. Dispos. 18(6):949-953.
182. Wong, S. L., Awni, W. M., Cavanaugh, J. H., El-Shourbagy, T., Locker, C. S., Dube, L. M. (1995). The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers. Clin. Pharmacokinet. 29(Suppl2 ):9-21.
183. Wood, S. G., John. B. A., Chasseaud, L. F., Yeh, J., Chung, M. (1987). The metabolism and pharmacokinetics of 14C-cetirizine in humans. Ann. Allergy 59(6, Part 2):31-34.
184. Woodworth, J. R., DeLong, A. F., Fasola, A. F., Oldham, S. (1991). 14C-Isomazole disposition in man after oral administration. Pharm. Res. 8(11):1413-1417.
185. Woodworth, J. R., Nyhart, E. H., Brier, G. L., Wolny, J. D., Black, H. R. (1992). Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimic. Agents Chemother. 36(2):318-325.
186. Young, G., Ellis, W., Ayrton, J., Hussey, E., Adamkiewicz, B. (2001). Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique. Xenobiotica 31(8/9):619-632.
187. Yuan, J. J., Yang, D. C., Zhang, J. Y., Bible, R., Karim, A., Findlay, J. W. A. (2002). Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. Drug Metab. Dispos. 30(9):1013-1021.
188. Zhang, D., Krishna, R., Wang, L., Zeng, J., Mitroka, J., Dai, R., Narasimhan, N., Reeves, R. A., Srinivas, N. R., Klunk, L. J. (2005). Metabolism, pharmacokinetics, and protein covalent binding of radiolabeled maxipost (BMS-204352) in humans. Drug Metab. Dispos. 33(1):83-93.
189. Zhi, J., Melia, A. T., Funk, C., Viger-Chougnet, A., Hopfgartner, G., Lausecker, B., Wang, K., Fulton, J. S., Gabriel, L., Mulligan, T. E. (1996). Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J. Clin. Pharmacol. 36(11):1006-1011.